Biomimetic Collagen Scaffolds Natural Cross‐Linking Strategies via Transglutaminase and Methylglyoxal for Skin Repair
Journal of Biomedical Materials Research Part A · 2026-07 · 114 (7)
DOI: 10.1002/jbm.a.70104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, online erschienen am 03.07.2026. Verfasst von Mina Vaez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Dentistry, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Transglutaminases, Pyruvaldehyde, Tissue Scaffolds, Collagen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, Ontario Research Foundation.
Abstract (Originalsprache)
Collagen‐based scaffolds are widely used in tissue engineering for skin repair due to their biocompatibility and structural resemblance to extracellular matrix. However, rapid degradation and insufficient mechanical stability limit their effectiveness. This study investigates natural cross‐linking strategies utilizing Transglutaminase (TG) and Methylglyoxal (MGO) to enhance scaffold durability while maintaining biocompatibility. Monolayer and bilayer collagen scaffolds were fabricated and cross‐linked using enzymatic (TG) and non‐enzymatic (MGO) treatments. Cross‐linking efficiency was assessed via TNBS/Hydroxyproline assays, while AFM and mechanical testing evaluated structural and mechanical properties. Cell viability (LIVE/DEAD), metabolic activity (MTS assay), and cell migration (in‐growth and out‐growth assays) were analyzed to assess biocompatibility and scaffold functionality. Wound healing was also assessed histologically. TG and MGO crosslinking significantly enhanced collagen fibril organization, scaffold stiffness, and enzymatic resistance. TG‐ and MGO‐treated scaffolds exhibited a homogeneous fibrillar structure with improved mechanical integrity. Both cross‐linking strategies supported high fibroblast viability and sustained metabolic activity over time. Migration assays confirmed that TG and MGO scaffolds facilitated fibroblast infiltration and wound closure. In vivo, the bilayer scaffolds with TG/MGO cross‐linking showed full epithelialization, with the Tg/25 MGO group exhibiting reduced inflammation, organized collagen, and hair follicle formation, suggesting improved regeneration. These findings highlight the potential of biomimetic collagen scaffolds as wound dressings for dermal tissue regeneration and skin repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Dentistry, University of Toronto, Toronto, Canada.
- Institute of Biomedical Engineering, University of Toronto, Toronto, Canada.
- Centro de Medicina Regenerativa, Facultad de Medicina Clínica Alemana-Universidad del Desarrollo, Santiago, Chile.
ORCID-Profile: Mina Vaez, Aiman Ali, Christina M Schuh, Laurent Bozec
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Ontario Research Foundation
Zitieren
APA
Vaez, M., Yen, M., Ali, A., Huang, S., Zhong, L., Schuh, C. M., & Bozec, L. (2026). Biomimetic Collagen Scaffolds Natural Cross‐Linking Strategies via Transglutaminase and Methylglyoxal for Skin Repair. Journal of Biomedical Materials Research Part A, 114(7). https://doi.org/10.1002/jbm.a.70104
Vancouver
Vaez M, Yen M, Ali A, Huang S, Zhong L, Schuh CM, et al. Biomimetic Collagen Scaffolds Natural Cross‐Linking Strategies via Transglutaminase and Methylglyoxal for Skin Repair. Journal of Biomedical Materials Research Part A. 2026;114(7). doi:10.1002/jbm.a.70104
BibTeX
@article{Vaez2026,
author = {Vaez, Mina and Yen, Matthew and Ali, Aiman and Huang, Sophia and Zhong, Liyang and Schuh, Christina M and Bozec, Laurent},
title = {Biomimetic Collagen Scaffolds Natural Cross‐Linking Strategies via Transglutaminase and Methylglyoxal for Skin Repair},
journal = {Journal of Biomedical Materials Research Part A},
year = {2026},
volume = {114},
number = {7},
doi = {10.1002/jbm.a.70104}
}
EUVIMED